Funding for Programs

Promiliad has been exceptionally successful in receiving highly competitive awards from the National Institutes of Health for our antibiotic development programs. To date we have been awarded multiple phase I and phase II SBIR/STTR awards, totaling over $6 million in non-dilutive funds.


2013 Development of stable

isosteres of dihydrofolate

reductase inhibitors as

antibacterial agents